FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510100699> ?p ?o ?g. }

• W2510100699 endingPage "650" @default.
• W2510100699 startingPage "645" @default.
• W2510100699 abstract "Abstract Background and Aims Daclatasvir and asunaprevir combination therapy has shown a high virological response for chronic genotype 1 hepatitis C virus (HCV) infected‐patients. However, the real‐world efficacy and safety of the therapy for patients with cirrhosis are unknown. Methods A total of 252 patients with genotype 1 HCV infection (158 with chronic hepatitis and 94 with compensated liver cirrhosis) were treated with 24 weeks of daclatasvir and asunaprevir combination therapy. Plasma concentrations of daclatasvir and asunaprevir at day 5 of treatment, end‐of‐treatment response, sustained virological response (SVR), and the frequencies of adverse events were analyzed. Result Plasma asunaprevir concentration was significantly higher, and daclatasvir concentration tended to be higher, in cirrhosis patients compared with chronic hepatitis patients. End‐of‐treatment response was achieved in 95.6% and 94.7% of chronic hepatitis and cirrhosis patients, respectively, and SVR was achieved in 94.3% and 92.6%. Although pre‐treatment NS5A drug resistant‐associated variants were detected, a high SVR rate was achieved when the population frequency of the variant was low. The frequencies of treatment‐related adverse events in cirrhosis patients were similar to those in chronic hepatitis patients. Treatment discontinuation due to adverse events occurred in three and two patients in chronic hepatitis and cirrhosis groups, respectively; however, four out of five patients with treatment discontinuation nonetheless achieved SVR. Conclusion Patients with compensated liver cirrhosis have similar virological response and tolerance for daclatasvir plus asunaprevir therapy to patients with chronic hepatitis. This combination therapy might offer a safe and effective treatment for chronic HCV infected‐patients with compensated cirrhosis." @default.
• W2510100699 created "2016-09-16" @default.
• W2510100699 creator A5004807660 @default.
• W2510100699 creator A5013840076 @default.
• W2510100699 creator A5018431544 @default.
• W2510100699 creator A5019195799 @default.
• W2510100699 creator A5021393447 @default.
• W2510100699 creator A5022484621 @default.
• W2510100699 creator A5023958825 @default.
• W2510100699 creator A5026178160 @default.
• W2510100699 creator A5027196488 @default.
• W2510100699 creator A5027695992 @default.
• W2510100699 creator A5031469873 @default.
• W2510100699 creator A5034077858 @default.
• W2510100699 creator A5035574974 @default.
• W2510100699 creator A5044269436 @default.
• W2510100699 creator A5051242188 @default.
• W2510100699 creator A5056103416 @default.
• W2510100699 creator A5070035943 @default.
• W2510100699 creator A5074699709 @default.
• W2510100699 creator A5083881674 @default.
• W2510100699 creator A5086666355 @default.
• W2510100699 date "2017-03-01" @default.
• W2510100699 modified "2023-10-03" @default.
• W2510100699 title "Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients" @default.
• W2510100699 cites W1551301313 @default.
• W2510100699 cites W1558399493 @default.
• W2510100699 cites W1965358723 @default.
• W2510100699 cites W1970220859 @default.
• W2510100699 cites W1984518799 @default.
• W2510100699 cites W1994851963 @default.
• W2510100699 cites W2000808124 @default.
• W2510100699 cites W2016703647 @default.
• W2510100699 cites W2027545702 @default.
• W2510100699 cites W2075293916 @default.
• W2510100699 cites W2083507900 @default.
• W2510100699 cites W2086409213 @default.
• W2510100699 cites W2088053309 @default.
• W2510100699 cites W2108873301 @default.
• W2510100699 cites W2109235725 @default.
• W2510100699 cites W2122717211 @default.
• W2510100699 cites W2125963799 @default.
• W2510100699 cites W2127685726 @default.
• W2510100699 cites W2157961528 @default.
• W2510100699 cites W2314685793 @default.
• W2510100699 cites W632840926 @default.
• W2510100699 doi "https://doi.org/10.1111/jgh.13511" @default.
• W2510100699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27513614" @default.
• W2510100699 hasPublicationYear "2017" @default.
• W2510100699 type Work @default.
• W2510100699 sameAs 2510100699 @default.
• W2510100699 citedByCount "9" @default.
• W2510100699 countsByYear W25101006992016 @default.
• W2510100699 countsByYear W25101006992017 @default.
• W2510100699 countsByYear W25101006992018 @default.
• W2510100699 countsByYear W25101006992020 @default.
• W2510100699 countsByYear W25101006992022 @default.
• W2510100699 crossrefType "journal-article" @default.
• W2510100699 hasAuthorship W2510100699A5004807660 @default.
• W2510100699 hasAuthorship W2510100699A5013840076 @default.
• W2510100699 hasAuthorship W2510100699A5018431544 @default.
• W2510100699 hasAuthorship W2510100699A5019195799 @default.
• W2510100699 hasAuthorship W2510100699A5021393447 @default.
• W2510100699 hasAuthorship W2510100699A5022484621 @default.
• W2510100699 hasAuthorship W2510100699A5023958825 @default.
• W2510100699 hasAuthorship W2510100699A5026178160 @default.
• W2510100699 hasAuthorship W2510100699A5027196488 @default.
• W2510100699 hasAuthorship W2510100699A5027695992 @default.
• W2510100699 hasAuthorship W2510100699A5031469873 @default.
• W2510100699 hasAuthorship W2510100699A5034077858 @default.
• W2510100699 hasAuthorship W2510100699A5035574974 @default.
• W2510100699 hasAuthorship W2510100699A5044269436 @default.
• W2510100699 hasAuthorship W2510100699A5051242188 @default.
• W2510100699 hasAuthorship W2510100699A5056103416 @default.
• W2510100699 hasAuthorship W2510100699A5070035943 @default.
• W2510100699 hasAuthorship W2510100699A5074699709 @default.
• W2510100699 hasAuthorship W2510100699A5083881674 @default.
• W2510100699 hasAuthorship W2510100699A5086666355 @default.
• W2510100699 hasConcept C126322002 @default.
• W2510100699 hasConcept C197934379 @default.
• W2510100699 hasConcept C203014093 @default.
• W2510100699 hasConcept C2522874641 @default.
• W2510100699 hasConcept C2776408679 @default.
• W2510100699 hasConcept C2776455275 @default.
• W2510100699 hasConcept C2776979040 @default.
• W2510100699 hasConcept C2777214474 @default.
• W2510100699 hasConcept C2778715236 @default.
• W2510100699 hasConcept C2780040827 @default.
• W2510100699 hasConcept C71924100 @default.
• W2510100699 hasConcept C90924648 @default.
• W2510100699 hasConceptScore W2510100699C126322002 @default.
• W2510100699 hasConceptScore W2510100699C197934379 @default.
• W2510100699 hasConceptScore W2510100699C203014093 @default.
• W2510100699 hasConceptScore W2510100699C2522874641 @default.
• W2510100699 hasConceptScore W2510100699C2776408679 @default.
• W2510100699 hasConceptScore W2510100699C2776455275 @default.
• W2510100699 hasConceptScore W2510100699C2776979040 @default.
• W2510100699 hasConceptScore W2510100699C2777214474 @default.

• next